Literature DB >> 16093436

The immunocytokine scFv23/TNF sensitizes HER-2/neu-overexpressing SKBR-3 cells to tumor necrosis factor (TNF) via up-regulation of TNF receptor-1.

Mi-Ae Lyu1, Michael G Rosenblum.   

Abstract

Overexpression of HER-2/neu confers cellular resistance to tumor necrosis factor (TNF)-mediated cytotoxicity to SKBR-3 breast cancer cell lines. To understand the correlation between HER-2/neu expression and TNF resistance, we examined the unique signaling pathways associated with the cytotoxic effects of the immunocytokine scFv23/TNF, recombinant single-chain antibody fusion constructs containing TNF and targeting HER-2/neu, in TNF-resistant SKBR-3-LP cells. We found that treatment of HER-2/neu-overexpressing SKBR-3-LP cells with scFv23/TNF resulted in a 5- to 7-fold higher level of TNF receptor-1 expression 48 hours after exposure. In addition, treatment of SKBR-3-LP cells with scFv23/TNF resulted in down-regulation of Akt phosphorylation and induced apoptosis through cleavage of caspase-8, caspase-3, and poly(ADP-ribose) polymerase. ScFv23/TNF-induced cytotoxicity was inhibited by blocking of the binding of the TNF component of scFv23/TNF to TNF receptor-1 and was dependent on activation of caspase-8 and caspase-3. These results indicate that the immunocytokine scFv23/TNF sensitizes TNF-resistant HER-2/neu-overexpressing SKBR-3-LP cells to TNF-induced apoptosis via the overexpression of TNF receptor-1 and suggest that the overexpression of TNF receptor-1 plays a crucial role in TNF sensitivity in HER-2/neu-overexpressing cancer cells. ScFv23/TNF targeting the HER-2/neu may be an effective cytotoxic agent against HER-2/neu-overexpressing cancer cells, which are inherently resistant to TNF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16093436     DOI: 10.1158/1535-7163.MCT-05-0014

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  8 in total

Review 1.  Issues related to targeted delivery of proteins and peptides.

Authors:  Yingjuan Lu; Jun Yang; Emanuela Sega
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

2.  The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.

Authors:  Yuying Liu; Weihe Zhang; Lawrence H Cheung; Ting Niu; Qingping Wu; Chun Li; Carolyn S Van Pelt; Michael G Rosenblum
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

Authors:  Weibo Cai; Zachary J Kerner; Hao Hong; Jiangtao Sun
Journal:  Biochem Insights       Date:  2008-07-22

Review 4.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

5.  Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice.

Authors:  Zhaohui Lu; Jiawei Ma; Bing Liu; Chungang Dai; Tao Xie; Xiaoyu Ma; Ming Li; Jun Dong; Qing Lan; Qiang Huang
Journal:  Cancer Med       Date:  2016-10-13       Impact factor: 4.452

Review 6.  The present and future of immunocytokines for cancer treatment.

Authors:  Dennis Y Gout; Lotte S Groen; Marjolein van Egmond
Journal:  Cell Mol Life Sci       Date:  2022-09-06       Impact factor: 9.207

7.  RGD-avidin-biotin pretargeting to alpha v beta 3 integrin enhances the proapoptotic activity of TNF alpha related apoptosis inducing ligand (TRAIL).

Authors:  Marc Tarrus; Almer M van der Sloot; Kai Temming; Marie Lacombe; Frank Opdam; Wim J Quax; Grietje Molema; Klaas Poelstra; Robbert J Kok
Journal:  Apoptosis       Date:  2008-02       Impact factor: 4.677

Review 8.  Utilizing Immunocytokines for Cancer Therapy.

Authors:  Erin Runbeck; Silvia Crescioli; Sophia N Karagiannis; Sophie Papa
Journal:  Antibodies (Basel)       Date:  2021-03-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.